DocGo Inc. (DCGO) Earnings Call Transcript & Summary

August 7, 2025

NASDAQ US Health Care Health Care Providers and Services earnings 28 min

Earnings Call Speaker Segments

Michael Cole

executive
#1

Thanks, Michael. Now, ahead of handing things to management, I want to offer a few comments about forward-looking statements. Everything shared on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, along with comparable expressions, might be employed to flag these forward-looking statements. Such forward-looking statements don't guarantee future performance, and we can't assure you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. Forward-looking statements carry inherent exposure to significant risks, uncertainties, and assumptions, a great many of which lie outside our control and could lead our actual results or outcomes, or when results or outcomes occur, to diverge materially from what our forward-looking statements contain; these risks, uncertainties, and assumptions encompass, without being limited to, those addressed in our risk factors and elsewhere in DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, our earnings release for this quarter, and other reports and statements DocGo has filed with the SEC, toward which your attention is directed. Actual outcomes and results, or when results or outcomes occur, might diverge materially from what these forward-looking statements express or imply. Additionally, references to non-GAAP financial measures appear in today's call. Reconciliations of these non-GAAP financial measures against the most directly comparable GAAP financial measures appear in our earnings release or the current report on Form 8-K that includes our earnings release and an exhibit containing additional information about certain non-GAAP financial measures, all of which are posted on our website, docgo.com, and furnished with the SEC. What you hear on this call is accurate as of the date discussed. Investors shouldn't assume statements will stay relevant and operative later on; we take on no obligation to update any information discussed on this call to reflect events or circumstances following the date of this call or to reflect new information or the occurrence of unanticipated events, except to the extent the law requires. At this point, it's my pleasure to hand the call to Mr. Lee Bienstock, CEO of DocGo. Lee, please go ahead.

Lee Bienstock

executive
#2

Thanks, Mike, and I appreciate everyone being here today. During our previous call, I explained how we're shaping DocGo around creative solutions for payers, providers, and health systems that change the way proactive healthcare gets delivered. I also expressed my confidence in the worth and robust market demand for our Mobile Health at any address and Medical Transportation platform. I'm extremely enthusiastic about the direction we're heading, and I'm happy to report our Q2 achievements, including a big boost to our cash balance, significant SG&A cuts, solid operational results, and securing several new contracts — all of which set us up to meet our 2025 objectives and seize the numerous growth possibilities in front of us. When it comes to our cash balance, we generated very robust operating cash flow this quarter, exceeding $30 million, as we kept making major strides gathering receivables from earlier migrant-related programs. In the prior quarter, we stated we had about $120 million in migrant-related accounts receivable. By the close of Q2, that figure now stands at approximately $54 million. Our total cash, encompassing cash and restricted cash and investments, reached $128.7 million at the conclusion of Q2, compared to $103.1 million in the previous quarter — a rise of $25.6 million; we still anticipate robust operating cash flow and total net cash exceeding $110 million by year-end. Alongside our solid cash collections, we advanced in cutting SG&A. At the end of Q2, we carried out a major reduction in force that removed dozens of positions in HR, finance, operations, and IT, and implemented further cuts to corporate overhead, leading to projected annualized savings of $10 million. We keep assessing our business structure to find more SG&A efficiencies and right-size when appropriate, while simultaneously striving to put ourselves in position to take advantage of growth prospects across each of our business verticals. We keep achieving considerable advancement on our key operational metrics. To illustrate the scale of our operations, this quarter we finished over 176,000 medical transports, over 6,000 Gap Closure and transitional care management visits, and over 28,000 mobile phlebotomy visits, meeting our targets and all in line with our aim of delivering healthcare to any address. The demand for proactive healthcare at any address has never been more urgent than now. Chronic disease represents the greatest challenge in American healthcare, with trillions of dollars spent annually treating it, posing a major difficulty for payers, providers, hospitals, and the entire U.S. healthcare system. We observe payers grappling with these issues, such as risk-pool deterioration and rising medical loss ratios; we think we're helping tackle the underlying causes of these problems. We're already collaborating with an impressive list of clients to deliver proactive care to individuals where they are, when they require it, and doing so on a large scale. Like I usually do, I'd like to take a few minutes to go over how things are going in each of those verticals: payers and providers, health systems, and government population health. To start with our payer and provider vertical, we're still making substantial headway — we just rolled out a brand-new Care Gap Closure Program down in Southern California alongside one of the biggest not-for-profit Medicare and Medicaid public health plans anywhere in the U.S. We're not only continuing to grow aggressively with the customers we already have in the Northeast and California, but we also expect to add services across multiple payers in over 18 new states by the close of 2026. Beyond our Care Gap Closure Program, there's strong interest in our Transition to Care Program, which is built to deliver inpatient visits for patients who were recently discharged so that readmissions go down. What began as an early pilot for these services at a single hospital in Southern California is now growing to 4 locations, where an on-site transition coordinator will assist with managing discharges at high risk for readmission across every business line for this payer. This ranks among our most significant customer expansions so far, and it underscores that although relationships in this vertical do take time to mature, the customer base we've already signed has enormous potential for growth. Since our Care Gap Closure Program began, we've collectively surpassed 1.2 million assigned lives to engage, which is up from 900,000 only a quarter ago. Velocity in our Gap Closure business is increasing. During the first half of 2025, we've already finished more at-home visits than we managed in all of 2024. Patient conversions are also trending positively as we test, learn, and optimize our outreach strategies, with a 50% rise in patient conversions in Q2 compared with the prior quarter. We also broadened our Care Gap Closure relationship with a major insurance company in the Northeast so that it now covers primary care services. We keep investing to build our capacity and capabilities to keep up with this rising level of demand, and our payer vertical pipeline has never been stronger; we're already working with 2 of the top 10 national payers and are in active discussions with both of these customers to expand those contracts. On top of that, we are in contracting with 2 more of the top 10 national payers and have an additional 35 deals with payers at various stages in our business development pipeline. Our solutions address real issues for insurance payers, and clearly they are resonating with this audience. We're on track to finish the year at more than 31,000 Care Gap visits and believe we can raise that number to more than 54,000 by the end of 2026; we expect to convert a large percentage of these Care Gap patients to DocGo's primary care practice, which we believe represents a much larger revenue opportunity. We aren’t just expanding what we’re able to accomplish—we also keep advancing the boundary of what’s possible in terms of integrating technology, and now AI, into the way we run things, so we can connect with patients more efficiently and deliver care wherever it’s required. To illustrate, a text-based AI agent was created by our engineering group to handle scheduling reminders, confirmations, and rebooking automatically in 7 languages. Since its recent debut, that AI agent has already locked in more than 3,000 appointments, moved another 350 to new times, and reduced the time spent by our live operators by approximately 10%. We’re currently teaching this agent to enroll patients in Care Gap services too, and we’re eager to report further outcomes during upcoming calls. Next, within our Medical Transportation segment, as I noted earlier, we finished over 176,000 transports spanning our fee-for-service and leased-hour trips in the U.S. and the UK during the quarter, while we put resources and investment in place ahead of a significant new customer launch in New York that started on July 1st. That new deployment is anticipated to support record trip volumes and top-line revenue for our Medical Transportation business in the year’s second half.

Lee Bienstock

executive
#3

Our engineering team needed under five weeks to link our proprietary software platform with the electronic health record system belonging to this customer, and that connection provided the hospital with a single centralized location for ordering, tracking, and managing patient transportation across its entire health system. Beyond that, we finalized a multi-year contract for providing medical transport to the Albany-Stratton VA Medical Center, secured renewed medical transportation agreements with the City of Atlantic City as well as an academic medical center located in Wisconsin, and we continue growing our facility count alongside our trip volumes in Dallas, Texas. Third, when it comes to our population health vertical, the migrant-related programs are still being wound down, and the bulk of that work concludes in late June. We started working with the Mescalero Apache Tribe and the New Mexico Department of Health on an initiative to broaden availability of preventive wellness care, women's health services, chronic disease management, and behavioral health services for rural New Mexico communities; in addition, we announced a fresh contract for delivering mobile health vaccination services to San Diego County; and we keep selectively going after government and agency opportunities we consider evergreen, as opposed to those tied to emergency response or episodic work. Interest is emerging in areas such as behavioral health for the general population, a field where we gained considerable experience across the past couple of years. We will continue to provide updates on how things are going, and we plan to separately disclose and discuss the revenue effects of this municipal population health initiative, which Norm will address during his portion of the call. To wrap up, I want to mention that on June 19th, we celebrated two milestones at Nasdaq by ringing the closing bell: our company's 10-year anniversary and our 10 millionth patient interaction. These achievements speak to the size and significance of what we have accomplished. We have just finished the first decade of what is a 100-year effort to radically change the way healthcare is provided, and I believe there is boundless potential in front of us over the next 90 years and beyond. At this point, I'll turn things over to Norm, who will walk through the financials.

Norman Rosenberg

executive
#4

Thanks, Lee, and good afternoon to everyone. For Q2 of 2025, total revenue came in at $80.4 million, versus $164.9 million during the same quarter in 2024. That drop in revenue stemmed entirely from the government vertical, mostly from projects tied to migrants. As we've noted across the last several quarters, our work related to migrants hit its peak in Q4 of 2023 and Q1 of 2024, then started winding down in May of 2024 when we exited the HPD sites in New York City. By the close of 2024, we had pulled out of every HPD site, and what remained of the migrant work with New York City Health and Hospitals was largely finished as of June 30 this year, with a small amount of additional revenue anticipated to stretch into the second half. Mobile Health revenue in Q2 of 2025 reached $30.8 million, a decrease from $116.7 million in Q2 of last year, caused by the shrinking migrant revenues. This year's figure included roughly $18 million tied to migrant revenues along with under $1 million from government population health revenues, which we said earlier we would break out separately. Medical Transportation services revenue rose to $49.6 million in Q2 of 2025, up from the $48.2 million in transport revenues recorded in Q2 of 2024. Gains in Delaware, Tennessee, Pennsylvania, and New Jersey pushed revenues upward, more than offsetting the effect of our departure from Colorado, a market that was exclusively fee-for-service and failed to meet our threshold for scale. If Colorado is excluded from both periods, our underlying transportation revenues grew by about 7% year over year. During Q2, Medical Transportation revenues represented 62% of total consolidated revenue, while Mobile Health made up the other 38%. Adjusted EBITDA in Q2 of 2025 showed a loss of $6.1 million, against adjusted EBITDA of $17.2 million in Q2 of 2024. Adjusted gross margin, which strips out the impact of depreciation and amortization and is the margin measure we follow most closely, stood at 31.6% in Q2 of 2025, versus 33.9% in Q2 of 2024. In Q2 of 2025, adjusted gross margin for the Mobile Health segment was 32.5%, compared with 35.9% in Q2 of 2024, yet higher than the 30.8% adjusted gross margins in Q1 of 2025. We saw better margins in the early-stage payer and provider business. As that business keeps expanding, we anticipate improved utilization rates among our clinicians, who account for most of the cost of goods sold. We expect that better utilization will drive higher gross margins for this business line and keep lifting the overall Mobile Health segment going forward. In the Medical Transportation segment, adjusted gross margins came to 31.1% in Q2 of 2025, versus 29.1% in Q2 of 2024. Even with a 200 basis point gain compared to the same period last year, Medical Transportation margins faced pressure during Q2 from a number of things, among them the continued heavy recruitment of field staff — EMTs included — as we prepare for additional expansion in our core markets. The biggest effect showed up in New York, where we brought on field personnel over the quarter ahead of the July 1 start of work with a significant new health system client, the one Lee referred to earlier. Turning to operating costs, SG&A has risen considerably as a share of total revenues while migrant revenues have been tapering off across the last few quarters. In absolute dollar terms, however, SG&A expenses came in 7% below the prior-year figure for the second quarter of 2025 and fell 5% quarter over quarter. When we look at what we term recurring SG&A — adding back non-cash items like depreciation and stock comp along with non-recurring items that get added back for adjusted EBITDA purposes — we've achieved meaningful decreases both year over year and sequentially. For Q2, recurring SG&A totaled $3.2 million, which is 9% below Q1 of 2025, and $7.1 million, which is 18% below Q2 of 2024; we're removing costs from the business by cutting headcount throughout all shared services functions, and we keep driving down vendor expenses either by moving to cheaper providers or by securing competitive bids for those services. Throughout the rest of 2025, we'll stay focused on bringing our SG&A costs down. Now, turning to the outlook, we still anticipate achieving positive adjusted EBITDA in the latter half of next year; to illustrate, that would mean producing quarterly revenues somewhere in the $80 million to $85 million range, with gross margins of 33% to 35%, and with adjusted SG&A 5% to 10% below what we just saw in Q2 of 2025. We have confidence that our robust pipeline, our strong balance sheet, and these cost-cutting measures will let us carry out this plan; now, from a cash flow standpoint, Q2 was an exceptionally strong quarter. We produced $33.6 million in positive cash flow from operations as we kept collecting our older, larger invoices. Over the first six months of 2025, we've produced more than $43 million in cash flow from operations. As a result, our cash balances ended Q2 much higher than they were at the close of Q1 or the close of 2024, even with cash used for our stock buyback program and the purchase of PTI Health. As of June 30, 2025, our total cash and cash equivalents, including restricted cash and investments, stood at $128.7 million, an increase of more than $25 million over the $103.1 million at March 31, 2025, the highest quarter-end level we've recorded since the second quarter of 2023. Our accounts receivable kept declining, which reflects our cash collections and the wind-down in migrant-related revenues that we've seen since the middle of the second quarter of 2024. We made considerable progress during Q2 in collecting our municipal receivables. When the quarter wrapped up, our accounts receivable tied to the different migrant programs stood at roughly $54 million, and that amounted to under 50% of our overall AR. For comparison, migrant program-related AR was $120 million when Q1 closed, and $150 million when 2024 ended — and back then that made up about 71% of the company's total. From the launch of those programs through today, we've now brought in around 95% of all migrant-related revenues, and we feel we have solid visibility into, and complete confidence in, collecting every remaining amount still owed. The wind-down of migrant-related programs has certainly affected revenues, but in 2025 our balance sheet has gained considerably as this AR gets collected, which has driven better cash flow from operations. That gives us the resources required to back the pipeline Lee mentioned a moment ago, put money into our growth, and strengthen our balance sheet even more. Last week, we drew on our higher cash balances to clear the outstanding amounts on our line of credit, taking $30 million of debt off the balance sheet. Executing our stock buyback program was one of the ways we put our cash to work in the second quarter. Over that quarter, we bought back 2.5 million shares through open market purchases, spending an aggregate of about $5.1 million. So far in 2025, we've laid out nearly $11 million on repurchasing our stock. Our Board of Directors gave the go-ahead in June to extend the buyback program through December 31. Under the terms of that program, we have roughly $11 million left at present. With that, I'd like to hand the call back to Michael for Q&A. Michael, please go ahead.

Pito Chickering

analyst
#5

Thanks for letting me ask; it appears that individuals enrolled in the Care Gap Closure Programs rose from 900,000 during the prior quarter to 1.2 million in this one, yet the outlook for revenue and EBITDA remains the same. I believe you covered how those economics are structured, but could you explain why bringing an additional 30,000 patients into Care Gap coverage leaves this year's guidance untouched?

Lee Bienstock

executive
#6

Of course, and I appreciate the question. To begin, the growth in patient count stems from agreements already in place when the year began. We had been informed about these. Naturally, they came to fruition during the quarter, and our plan is to expand and build up operations so we can satisfy the demand. What matters most for us at this moment, given this larger patient roster, is raising our engagement rate among these individuals, while also boosting our capacity and our field teams so they can carry out every visit we're presently scheduling with these patient lists. That represents our major objective today — growing the field teams, ensuring they receive solid training so they can provide extremely high-quality service. For us, that's the crucial element at present as we expand through the latter half of the year.

Pito Chickering

analyst
#7

All right, that's helpful. Regarding Medical Transportation, revenue declined somewhat on a quarter-over-quarter basis, which is unusual for us. Could you break down the various components related to the Colorado exit? Did that business contribute any revenue during the first quarter that made the comparison tougher, or simply take us through how Medical Transportation revenue moved from Q1 to Q2 on a sequential basis?

Norman Rosenberg

executive
#8

Hi, this is Norm. When it comes to Colorado, there was hardly any revenue to speak of in Q1; the impact was really felt more in the year-over-year comparison. In Q2 of 2024, I believe there was roughly $1.8 million, something in that vicinity, coming from Colorado, while Q2 of 2025 had a negligible amount of revenue. The year-over-year effect mattered more than the sequential one; as for the slight decline from Q1 to Q2, seasonality played the biggest role; a few of our larger markets generated stronger revenues in the first quarter than we had anticipated. It was just a question of that normalizing.

Pito Chickering

analyst
#9

All right, sounds good. None of those agreements have been altered so that they reprice in a negative direction, or anything of that nature?

Norman Rosenberg

executive
#10

Not at all. What I'd say is that, if you take a look at, well, much of this ties together, correct? Since when you examine Q1, we were pushing right up against what I'd describe as certain of our capacity limits, correct? We ran the business during Q1 at a really elevated rate of capacity utilization, and that kind of brings about some of the greater cost of goods sold we saw in Q2, when we clearly needed to bring on staff so we could handle additional volume; that sort of thing is bound to occur. It isn't really a step function, yet what usually occurs is that, well, we'll operate our crews and our equipment at whatever maximum capacity we're able to extract from them. You reach a stage where you sort of need to pull back a bit and recalibrate, so that you're able to move up to the following level; that's what I'd say took place from Q1 to Q2.

Pito Chickering

analyst
#11

Okay, great, thank you very much.

Aditya Dagaonkar

analyst
#12

Hey, hello, Aditya here speaking for Mike Latimore. Could you provide some insight regarding the EBITDA margin for your Medical Transportation segment, and what do you expect it to be as a long-term objective?

Norman Rosenberg

executive
#13

I'll take that one. What I mean is, we have discussed our intention to achieve a double-digit EBITDA margin for that operation. In the quarter, that wasn't the situation. I'd describe it as likely mid-single digits for the quarter, roughly in the 5% or 6% range. We mentioned that gross margins came in, I'd say, about two points beneath our expectations. The main reason was what happened in New York, where, as we've mentioned, that market is our largest by size; we recently started with a big hospital system in New York, and that began on July 1. In the quarter, especially in the final month, June, we certainly increased our staffing. We had individuals undergoing training, we had individuals on the payroll, but clearly not yet operating trips. There was somewhat of a timing mismatch between cost of goods sold and revenue coming in. That dampened margins somewhat. Aside from that, we still believe that an EBITDA margin of 10% on an underlying basis for the transport business is quite achievable.

Aditya Dagaonkar

analyst
#14

Understood. As a share of your yearly revenue, where do you expect Medical Transportation to land this year?

Norman Rosenberg

executive
#15

During the last quarter, as we said, that figure came in at roughly 62%. It won't hold at that level; most likely it will decrease from there, since our health plan, payer, and provider operations are expanding considerably more quickly. On the Mobile Health side, those ancillary businesses are expanding too. My estimate is that for the year it will remain somewhere around 60% or so — 60% to 65%, compared with 35% to 40% for the segment we refer to as Mobile Health.

Aditya Dagaonkar

analyst
#16

Okay, thanks.

Lee Bienstock

executive
#17

Thanks, Michael. I’m grateful to everybody for spending time on today’s call and for the considerate questions. CMS estimated that spending on healthcare delivered in the home will increase twofold between 2021 and 2031, reaching roughly $250 billion. We think our organization sits at the leading edge of that movement—care provided in the home, delivering high-quality care there. We’re doing this at a size that we believe almost no other firms can equal, supported by a technology platform built for this purpose and agreements with several of the largest players in healthcare. Above all, patients are happy to welcome DocGo at their door. Thanks to our amazing team and to our investors as we turn our shared vision—healthcare at any address—into something real. We’re eager to talk with all of you again before long. Take care.

Operator

operator
#18

Everyone, that brings us to the end of today's call. We appreciate all of you joining in. You're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.